About Me
Consolato M. Sergi is full Professor of Pathology and Pediatrics (Adj. Prof.), University of Alberta, Edmonton, Canada. Dr. Sergi was born in Rome (Italy), obtained his MD degree with honors at the University of Genoa, Italy, Human Pathology degree at the University of Heidelberg, Germany, the title of hon. Clinical Reader at the University of Bristol, UK, Ph.D./Habilitation at the University of Innsbruck, Austria, MSc Public Health in Austria, and FRCPC degree at the Royal College in Ottawa. Dr. Sergi’s specialty areas of interest are congenital heart disease and metabolic diseases, biliary diseases, carcinogenesis (bone/soft tissue/liver), and mitochondrial DNA‐related cardiomyopathies.
Clinical Interests: Neonatal, Pediatric and Adult Cholestasis, Perinatal and Pediatric Liver Disease, Congenital Heart Disease, Metabolic Diseases, Ultrastructural (TEM/SEM) and Multi-Signaling-related (IF, CFLM) Analysis of Pediatric Diseases, Fetal, Perinatal and Pediatric Autopsy, Relevance of Teamwork and Quality Assurance in Diagnostic Services.
Teaching
Translation Medicine, Pediatric Histopathology and Signal Transduction Identification with Clinico-Pathological Correlation.
Research
- Pathology and Genetics of Hepato-Renal Fibrocystic Diseases with Development of Animal
- Models as well as Veterinary Pathology of KO and KI Models
- Etiology and Pathogenesis of Hepatocellular and Cholangiocellular Carcinoma
- Interaction of Insulin-Growth Factor Binding Proteins and Ubiquitin-Proteasome Pathway in Pediatric Tumors
- Mitochondrial DNA-related Cardiomyopathies and Neuro-Metabolic Diseases
- Detection of Homoplasmic and Heteroplasmic Mutations in Mitochondriopathies
-
Fellow College of Am. Pathologists
- College Of American Pathologists
- 2014
-
Fellow Royal College Pathologists
- Royal College Of Physicians & Surgeons
- 2013
-
Master of Public Health
- University of Innsbruck
- 2006
-
Doctor of Philosophy
- University of Innsbruck
- 2004
-
Medical Doctor
- University of Genoa
- 1989
-
Targeting IGF1R and its mediated super-enhancer by using RNA guided CRISPR/Cas9 nuclease for the therapy of osteosarcoma
- Funding Source: WCHRI
- Year Granted: 2017
- Research Role: Principal Investigator